OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 18, 2023 4:30pm EDT

OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 16, 2023 1:29pm EDT

OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

May 16, 2023 8:00am EDT

OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program

Apr 27, 2023 7:30am EDT

OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 11, 2023 2:06pm EDT

OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 10, 2023 11:32am EDT

OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

Apr 03, 2023 7:00am EDT

OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022

Dec 05, 2022 9:00am EST

OncoSec Announces Pricing of $3.5 Million Public Offering

Nov 30, 2022 9:15am EST

OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma

Nov 15, 2022 4:45pm EST